Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Comparison of in situ and extraction-based methods for the detection of MET amplifications in solid tumors.

Heydt C, Becher AK, Wagener-Ryczek S, Ball M, Schultheis AM, Schallenberg S, Rüsseler V, Büttner R, Merkelbach-Bruse S.

Comput Struct Biotechnol J. 2019 Sep 11;17:1339-1347. doi: 10.1016/j.csbj.2019.09.003. eCollection 2019.

2.

Comparison of in Situ and Extraction-Based Methods for the Detection of ROS1 Rearrangements in Solid Tumors.

Heydt C, Ruesseler V, Pappesch R, Wagener S, Haak A, Siebolts U, Riedel R, Michels S, Wolf J, Schultheis AM, Rehker J, Buettner R, Merkelbach-Bruse S.

J Mol Diagn. 2019 Nov;21(6):971-984. doi: 10.1016/j.jmoldx.2019.06.006. Epub 2019 Aug 2.

PMID:
31382035
3.

Acquired KRAS mutation and loss of low-level MET amplification after durable response to crizotinib in a patient with lung adenocarcinoma.

Riedel R, Michels S, Heydt C, Siemanowski J, Kobe C, Bunck A, Schäfer S, Fischer RN, Scheffler M, Abdulla DSY, Nogová L, Koleczko S, Merkelbach-Bruse S, Büttner R, Wolf J.

Lung Cancer. 2019 Jul;133:20-22. doi: 10.1016/j.lungcan.2019.05.006. Epub 2019 May 6.

PMID:
31200822
4.

Advance of theragnosis biomarkers in lung cancer: from clinical to molecular pathology and biology.

Alidousty C, Baar T, Heydt C, Wagener-Ryczek S, Kron A, Wolf J, Buettner R, Schultheis AM.

J Thorac Dis. 2019 Jan;11(Suppl 1):S3-S8. doi: 10.21037/jtd.2018.12.03. Review.

5.

Alterations in ERBB2 and BRCA and microsatellite instability as new personalized treatment options in small bowel carcinoma.

Quaas A, Heydt C, Waldschmidt D, Alakus H, Zander T, Goeser T, Kasper P, Bruns C, Brunn A, Roth W, Hartmann N, Bunck A, Schmidt M, Buettner R, Merkelbach-Bruse S.

BMC Gastroenterol. 2019 Feb 4;19(1):21. doi: 10.1186/s12876-019-0942-z.

6.

K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways.

Scheffler M, Ihle MA, Hein R, Merkelbach-Bruse S, Scheel AH, Siemanowski J, Brägelmann J, Kron A, Abedpour N, Ueckeroth F, Schüller M, Koleczko S, Michels S, Fassunke J, Pasternack H, Heydt C, Serke M, Fischer R, Schulte W, Gerigk U, Nogova L, Ko YD, Abdulla DSY, Riedel R, Kambartel KO, Lorenz J, Sauerland I, Randerath W, Kaminsky B, Hagmeyer L, Grohé C, Eisert A, Frank R, Gogl L, Schaepers C, Holzem A, Hellmich M, Thomas RK, Peifer M, Sos ML, Büttner R, Wolf J.

J Thorac Oncol. 2019 Apr;14(4):606-616. doi: 10.1016/j.jtho.2018.12.013. Epub 2018 Dec 31.

7.

Comparison of the genomic background of MET-altered carcinomas of the lung: biological differences and analogies.

Castiglione R, Alidousty C, Holz B, Wagener S, Baar T, Heydt C, Binot E, Zupp S, Kron A, Wolf J, Merkelbach-Bruse S, Reinhardt HC, Buettner R, Schultheis AM.

Mod Pathol. 2019 May;32(5):627-638. doi: 10.1038/s41379-018-0182-8. Epub 2018 Nov 20.

8.

Overcoming EGFRG724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors.

Fassunke J, Müller F, Keul M, Michels S, Dammert MA, Schmitt A, Plenker D, Lategahn J, Heydt C, Brägelmann J, Tumbrink HL, Alber Y, Klein S, Heimsoeth A, Dahmen I, Fischer RN, Scheffler M, Ihle MA, Priesner V, Scheel AH, Wagener S, Kron A, Frank K, Garbert K, Persigehl T, Püsken M, Haneder S, Schaaf B, Rodermann E, Engel-Riedel W, Felip E, Smit EF, Merkelbach-Bruse S, Reinhardt HC, Kast SM, Wolf J, Rauh D, Büttner R, Sos ML.

Nat Commun. 2018 Nov 7;9(1):4655. doi: 10.1038/s41467-018-07078-0.

9.

Genomic Characterization of TP53-Wild-Type Esophageal Carcinoma.

Quaas A, Heydt C, Gebauer F, Alakus H, Loeser H, Buettner R, Hillmer A, Bruns C, Merkelbach-Bruse S, Zander T, Frommolt P.

Transl Oncol. 2019 Jan;12(1):154-161. doi: 10.1016/j.tranon.2018.09.007. Epub 2018 Oct 11. No abstract available.

10.

Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer.

Kron A, Alidousty C, Scheffler M, Merkelbach-Bruse S, Seidel D, Riedel R, Ihle MA, Michels S, Nogova L, Fassunke J, Heydt C, Kron F, Ueckeroth F, Serke M, Krüger S, Grohe C, Koschel D, Benedikter J, Kaminsky B, Schaaf B, Braess J, Sebastian M, Kambartel KO, Thomas R, Zander T, Schultheis AM, Büttner R, Wolf J.

Ann Oncol. 2018 Oct 1;29(10):2068-2075. doi: 10.1093/annonc/mdy333.

11.

Comparative proteomics reveals a diagnostic signature for pulmonary head-and-neck cancer metastasis.

Bohnenberger H, Kaderali L, Ströbel P, Yepes D, Plessmann U, Dharia NV, Yao S, Heydt C, Merkelbach-Bruse S, Emmert A, Hoffmann J, Bodemeyer J, Reuter-Jessen K, Lois AM, Dröge LH, Baumeister P, Walz C, Biggemann L, Walter R, Häupl B, Comoglio F, Pan KT, Scheich S, Lenz C, Küffer S, Bremmer F, Kitz J, Sitte M, Beißbarth T, Hinterthaner M, Sebastian M, Lotz J, Schildhaus HU, Wolff H, Danner BC, Brandts C, Büttner R, Canis M, Stegmaier K, Serve H, Urlaub H, Oellerich T.

EMBO Mol Med. 2018 Sep;10(9). pii: e8428. doi: 10.15252/emmm.201708428.

12.

Genetic instability and recurrent MYC amplification in ALK-translocated NSCLC: a central role of TP53 mutations.

Alidousty C, Baar T, Martelotto LG, Heydt C, Wagener S, Fassunke J, Duerbaum N, Scheel AH, Frank S, Holz B, Binot E, Kron A, Merkelbach-Bruse S, Ihle MA, Wolf J, Buettner R, Schultheis AM.

J Pathol. 2018 Sep;246(1):67-76. doi: 10.1002/path.5110. Epub 2018 Jul 31.

13.

Therapy susceptible germline-related BRCA 1-mutation in a case of metastasized mixed adeno-neuroendocrine carcinoma (MANEC) of the small bowel.

Quaas A, Waldschmidt D, Alakus H, Zander T, Heydt C, Goeser T, Daheim M, Kasper P, Plum P, Bruns C, Brunn A, Roth W, Hartmann N, Bunck A, Schmidt M, Göbel H, Tharun L, Buettner R, Merkelbach-Bruse S.

BMC Gastroenterol. 2018 May 31;18(1):75. doi: 10.1186/s12876-018-0803-1.

14.

Novel approaches against epidermal growth factor receptor tyrosine kinase inhibitor resistance.

Heydt C, Michels S, Thress KS, Bergner S, Wolf J, Buettner R.

Oncotarget. 2018 Mar 8;9(20):15418-15434. doi: 10.18632/oncotarget.24624. eCollection 2018 Mar 16. Review.

15.

Clinical and Pathological Characteristics of KEAP1- and NFE2L2-Mutated Non-Small Cell Lung Carcinoma (NSCLC).

Frank R, Scheffler M, Merkelbach-Bruse S, Ihle MA, Kron A, Rauer M, Ueckeroth F, König K, Michels S, Fischer R, Eisert A, Fassunke J, Heydt C, Serke M, Ko YD, Gerigk U, Geist T, Kaminsky B, Heukamp LC, Clement-Ziza M, Büttner R, Wolf J.

Clin Cancer Res. 2018 Jul 1;24(13):3087-3096. doi: 10.1158/1078-0432.CCR-17-3416. Epub 2018 Apr 3.

16.

The landscape of genetic alterations in ameloblastomas relates to clinical features.

Gültekin SE, Aziz R, Heydt C, Sengüven B, Zöller J, Safi AF, Kreppel M, Buettner R.

Virchows Arch. 2018 May;472(5):807-814. doi: 10.1007/s00428-018-2305-5. Epub 2018 Feb 1.

17.

An evaluation of the challenges to developing tumor BRCA1 and BRCA2 testing methodologies for clinical practice.

Ellison G, Ahdesmäki M, Luke S, Waring PM, Wallace A, Wright R, Röthlisberger B, Ludin K, Merkelbach-Bruse S, Heydt C, Ligtenberg MJL, Mensenkamp AR, de Castro DG, Jones T, Vivancos A, Kondrashova O, Pauwels P, Weyn C, Hahnen E, Hauke J, Soong R, Lai Z, Dougherty B, Carr TH, Johnson J, Mills J, Barrett JC.

Hum Mutat. 2018 Mar;39(3):394-405. doi: 10.1002/humu.23375. Epub 2017 Dec 28.

18.

Comparison of Blood Collection Tubes from Three Different Manufacturers for the Collection of Cell-Free DNA for Liquid Biopsy Mutation Testing.

Alidousty C, Brandes D, Heydt C, Wagener S, Wittersheim M, Schäfer SC, Holz B, Merkelbach-Bruse S, Büttner R, Fassunke J, Schultheis AM.

J Mol Diagn. 2017 Sep;19(5):801-804. doi: 10.1016/j.jmoldx.2017.06.004. Epub 2017 Jul 18.

PMID:
28732213
19.

Copy-number variation and protein expression of DOT1L in pancreatic adenocarcinoma as a potential drug target.

Loeser H, Waldschmidt D, Kuetting F, Heydt C, Zander T, Plum P, Alakus H, Buettner R, Quaas A.

Mol Clin Oncol. 2017 May;6(5):639-642. doi: 10.3892/mco.2017.1194. Epub 2017 Mar 14.

20.

KRAS mutation in papillary fibroelastoma: a true cardiac neoplasm?

Wittersheim M, Heydt C, Hoffmann F, Büttner R.

J Pathol Clin Res. 2017 Mar 7;3(2):100-104. doi: 10.1002/cjp2.66. eCollection 2017 Apr.

21.

Use of the GeneReader NGS System in a clinical pathology laboratory: a comparative study.

Koitzsch U, Heydt C, Attig H, Immerschitt I, Merkelbach-Bruse S, Fammartino A, Büttner RH, Kong Y, Odenthal M.

J Clin Pathol. 2017 Aug;70(8):725-728. doi: 10.1136/jclinpath-2017-204342. Epub 2017 Apr 11.

22.

ALKG1269A mutation as a potential mechanism of acquired resistance to crizotinib in an ALK-rearranged inflammatory myofibroblastic tumor.

Michels SYF, Scheel AH, Wündisch T, Heuckmann JM, Menon R, Puesken M, Kobe C, Pasternack H, Heydt C, Scheffler M, Fischer R, Schultheis AM, Merkelbach-Bruse S, Heukamp L, Büttner R, Wolf J.

NPJ Precis Oncol. 2017 Mar 20;1(1):4. doi: 10.1038/s41698-017-0004-3. eCollection 2017.

23.

[BRCA diagnostics of ovarian cancer : Molecular tumor testing since the introduction of PARP inhibitor therapy].

Löser H, Heydt C, Büttner R, Markiefka B.

Pathologe. 2017 Mar;38(2):117-126. doi: 10.1007/s00292-017-0274-0. German.

PMID:
28258387
24.

ALK evaluation in the world of multiplex testing: Network Genomic Medicine (NGM): the Cologne model for implementing personalised oncology.

Heydt C, Kostenko A, Merkelbach-Bruse S, Wolf J, Büttner R.

Ann Oncol. 2016 Sep;27 Suppl 3:iii25-iii34. doi: 10.1093/annonc/mdw303. Review.

PMID:
27573753
25.

Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors.

Ortiz-Cuaran S, Scheffler M, Plenker D, Dahmen L, Scheel AH, Fernandez-Cuesta L, Meder L, Lovly CM, Persigehl T, Merkelbach-Bruse S, Bos M, Michels S, Fischer R, Albus K, König K, Schildhaus HU, Fassunke J, Ihle MA, Pasternack H, Heydt C, Becker C, Altmüller J, Ji H, Müller C, Florin A, Heuckmann JM, Nuernberg P, Ansén S, Heukamp LC, Berg J, Pao W, Peifer M, Buettner R, Wolf J, Thomas RK, Sos ML.

Clin Cancer Res. 2016 Oct 1;22(19):4837-4847. Epub 2016 Jun 1.

26.

Genetische Grundlagen eines solitären familiären plexiformen Neurofibroms ohne verifizierte begleitende Neurofibromatose.

Jungmann J, Heydt C, Bohle R, Pföhler C, Vogt T, Müller CS.

J Dtsch Dermatol Ges. 2016 May;14(5):525-8. doi: 10.1111/ddg.12990_g. No abstract available.

PMID:
27119483
27.

Genetic basis of a solitary familial plexiform neurofibroma without verified associated neurofibromatosis.

Jungmann J, Heydt C, Bohle R, Pföhler C, Vogt T, Müller CS.

J Dtsch Dermatol Ges. 2016 May;14(5):525-7. doi: 10.1111/ddg.12990. No abstract available.

PMID:
27119482
28.

The impact of sequencing on diagnosis and treatment of malignant melanoma.

Castiglione R, Ihle MA, Heydt C, Schultheis AM, Merkelbach-Bruse S, Mauch C, Büttner R.

Expert Rev Mol Diagn. 2016;16(4):423-33. doi: 10.1586/14737159.2016.1147958. Epub 2016 Feb 19. Review.

PMID:
26822148
29.

Clinicopathological Characteristics of RET Rearranged Lung Cancer in European Patients.

Michels S, Scheel AH, Scheffler M, Schultheis AM, Gautschi O, Aebersold F, Diebold J, Pall G, Rothschild S, Bubendorf L, Hartmann W, Heukamp L, Schildhaus HU, Fassunke J, Ihle MA, Künstlinger H, Heydt C, Fischer R, Nogovà L, Mattonet C, Hein R, Adams A, Gerigk U, Schulte W, Lüders H, Grohé C, Graeven U, Müller-Naendrup C, Draube A, Kambartel KO, Krüger S, Schulze-Olden S, Serke M, Engel-Riedel W, Kaminsky B, Randerath W, Merkelbach-Bruse S, Büttner R, Wolf J.

J Thorac Oncol. 2016 Jan;11(1):122-7. doi: 10.1016/j.jtho.2015.09.016.

30.

Implementation of Amplicon Parallel Sequencing Leads to Improvement of Diagnosis and Therapy of Lung Cancer Patients.

König K, Peifer M, Fassunke J, Ihle MA, Künstlinger H, Heydt C, Stamm K, Ueckeroth F, Vollbrecht C, Bos M, Gardizi M, Scheffler M, Nogova L, Leenders F, Albus K, Meder L, Becker K, Florin A, Rommerscheidt-Fuss U, Altmüller J, Kloth M, Nürnberg P, Henkel T, Bikár SE, Sos ML, Geese WJ, Strauss L, Ko YD, Gerigk U, Odenthal M, Zander T, Wolf J, Merkelbach-Bruse S, Buettner R, Heukamp LC.

J Thorac Oncol. 2015 Jul;10(7):1049-57. doi: 10.1097/JTO.0000000000000570.

31.

FGFR2 is overexpressed in myxoid liposarcoma and inhibition of FGFR signaling impairs tumor growth in vitro.

Künstlinger H, Fassunke J, Schildhaus HU, Brors B, Heydt C, Ihle MA, Mechtersheimer G, Wardelmann E, Büttner R, Merkelbach-Bruse S.

Oncotarget. 2015 Aug 21;6(24):20215-30.

32.

miRNA-221 and miRNA-222 induce apoptosis via the KIT/AKT signalling pathway in gastrointestinal stromal tumours.

Ihle MA, Trautmann M, Kuenstlinger H, Huss S, Heydt C, Fassunke J, Wardelmann E, Bauer S, Schildhaus HU, Buettner R, Merkelbach-Bruse S.

Mol Oncol. 2015 Aug;9(7):1421-33. doi: 10.1016/j.molonc.2015.03.013. Epub 2015 Apr 10.

33.

Massively parallel sequencing fails to detect minor resistant subclones in tissue samples prior to tyrosine kinase inhibitor therapy.

Heydt C, Kumm N, Fassunke J, Künstlinger H, Ihle MA, Scheel A, Schildhaus HU, Haller F, Büttner R, Odenthal M, Wardelmann E, Merkelbach-Bruse S.

BMC Cancer. 2015 Apr 15;15:291. doi: 10.1186/s12885-015-1311-0.

34.

MET gene copy number alterations and expression of MET and hepatocyte growth factor are potential biomarkers in angiosarcomas and undifferentiated pleomorphic sarcomas.

Schmitz K, Koeppen H, Binot E, Fassunke J, Künstlinger H, Ihle MA, Heydt C, Wardelmann E, Büttner R, Merkelbach-Bruse S, Rüschoff J, Schildhaus HU.

PLoS One. 2015 Apr 6;10(4):e0120079. doi: 10.1371/journal.pone.0120079. eCollection 2015.

35.

PIK3CA mutations in non-small cell lung cancer (NSCLC): genetic heterogeneity, prognostic impact and incidence of prior malignancies.

Scheffler M, Bos M, Gardizi M, König K, Michels S, Fassunke J, Heydt C, Künstlinger H, Ihle M, Ueckeroth F, Albus K, Serke M, Gerigk U, Schulte W, Töpelt K, Nogova L, Zander T, Engel-Riedel W, Stoelben E, Ko YD, Randerath W, Kaminsky B, Panse J, Becker C, Hellmich M, Merkelbach-Bruse S, Heukamp LC, Büttner R, Wolf J.

Oncotarget. 2015 Jan 20;6(2):1315-26.

36.

Comparison of pre-analytical FFPE sample preparation methods and their impact on massively parallel sequencing in routine diagnostics.

Heydt C, Fassunke J, Künstlinger H, Ihle MA, König K, Heukamp LC, Schildhaus HU, Odenthal M, Büttner R, Merkelbach-Bruse S.

PLoS One. 2014 Aug 8;9(8):e104566. doi: 10.1371/journal.pone.0104566. eCollection 2014.

37.

[Biomarker analysis from a pathologist's view. Founding the rationale for personalised treatment of lung cancer].

Buettner R, Heydt C.

Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2013 Nov;56(11):1502-8. doi: 10.1007/s00103-013-1823-1. Review. German.

PMID:
24170079
39.

Loss of cell cycle controls in apoptotic lymphoblasts of the bursa of Fabricius.

Neiman PE, Blish C, Heydt C, Loring G, Thomas SJ.

Mol Biol Cell. 1994 Jul;5(7):763-72.

Supplemental Content

Support Center